Skip to main content

Kymera Therapeutics, Inc.

KYMR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001815442

In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Kymera Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
6 filings
5 insiders, $33.5M in total
Insiders trading
5
Net value
−$33.5M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Kymera Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Kymera Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Adams BrianChief Legal Officer50,254Sep 4, 20262
Rooney TerenceChief Medical Officer38,000Jul 27, 20261
Mainolfi NelloChief Executive Officer666,568Jul 7, 202610
Jacobs Bruce N.Chief Financial Officer244,883Jul 2, 20264
Goodman NoahChief Business Officer47,179Jul 2, 20266
Booth BruceDirector462,856IndirectJul 2, 202612
Biotechnology Value Fund L PDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
BVF Partners L PDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
BVF IncDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
Biotechnology Value Fund II LPDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
Lampert Mark NDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
Biotechnology Value Trading Fund OS LPDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
BVF Partners OS Ltd.Director, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
BVF I GP LLCDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
BVF II GP LLCDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
BVF GP Holdings LLCDirector, Other: See Remarks and Footnotes78,787IndirectJun 26, 20262
Baker JulianDirector, 10% Owner7,955,916IndirectJun 25, 20262
Baker FelixDirector, 10% Owner7,955,916IndirectJun 25, 20262
Baker Bros. Advisors LPDirector, 10% Owner7,955,916IndirectJun 25, 20262
Baker Brothers Life Sciences LPDirector, 10% Owner7,955,916IndirectJun 25, 20262
667, L.P.Director, 10% Owner7,955,916IndirectJun 25, 20262
Baker Bros. Advisors (GP) LLCDirector, 10% Owner7,955,916IndirectJun 25, 20262
Maraganore JohnDirector–Jun 25, 20261
Sandor VictorDirector–Jun 25, 20261
Albers Jeffrey W.Director0Jun 25, 20263
Esposito PamelaDirector1,000Jun 25, 20266
Ridloff ElenaDirector0Jun 25, 20263
Hrustanovic GorjanDirector–Jun 25, 20261
Chadwick Jeremy GChief Operating Officer44,018May 27, 20267
Gollob JaredChief Medical Officer117,134Mar 4, 20264
Chiniara EllenChief Legal Officer80,085Mar 3, 20250
Morgan LeighDirector–Jun 20, 20240
Horobin JoannaDirector0Jun 7, 20240
Atlas Venture Fund X, L.P.10% Owner828,830IndirectMar 13, 20240
Atlas Venture Associates X, LLC10% Owner828,830IndirectMar 13, 20240
Atlas Venture Associates X, L.P.10% Owner828,830IndirectMar 13, 20240
Atlas Venture Opportunity Fund I, L.P.10% Owner828,830IndirectMar 13, 20240
Atlas Venture Associates Opportunity I, L.P.10% Owner828,830IndirectMar 13, 20240
Atlas Venture Associates Opportunity I, LLC10% Owner828,830IndirectMar 13, 20240
Caughey ElaineChief Business Officer18,986Mar 3, 20230
Nicholson Donald WilliamDirector–Jun 16, 20220
Chesworth RichardChief Scientific Officer0Aug 27, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 14, 2025 (view filing)Oct 131 dayAlbers Jeffrey W.DirectorSSale−5.00K$59.19−$295.9K−100.0%0 after10b5-1
Sep 17, 2025 (view filing)Sep 17Same dayJacobs Bruce N.Chief Financial OfficerSSale−79.2K$50.00−$3.96M−25.8%227.4K after10b5-1
Sep 16, 2025 (view filing)Sep 16Same dayMainolfi NelloChief Executive OfficerSSale−30.0K$49.00−$1.47M−4.3%660.5K after10b5-1
Jul 1, 2025 (view filing)6:41 PM ETJun 301 dayBiotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and FootnotesPPurchaseCommon Stock, $0.0001 par value+317.2K$44.00+$14.0M+875.1%353.4K after3 lots
Jun 30, 2025 (view filing)8:15 PM ETJun 30Same dayBaker Julian and 5 othersDirectorPPurchase+655.5K$44.00+$28.8M+12.0%6.12M after2 lots
Jun 30, 2025 (view filing)8:15 PM ETJun 30Same dayBaker Julian and 5 othersDirectorPPurchase+655.5K$44.00+$28.8M–10.2M afterDerivative2 lots
Jun 11, 2025 (view filing)Jun 11Same dayRidloff ElenaDirectorSSale−4.50K$50.00−$225.0K−100.0%0 after10b5-1
Jun 3, 2025 (view filing)Jun 3Same dayEsposito PamelaDirectorSSale−5.00K$49.04−$245.2K−100.0%0 after10b5-1
Jun 3, 2025 (view filing)Jun 3Same dayRidloff ElenaDirectorSSale−12.0K$46.10−$553.2K−100.0%0 after2 lots10b5-1
Jun 3, 2025 (view filing)Jun 3Same dayMainolfi NelloChief Executive OfficerSSale−30.0K$49.00−$1.47M−4.3%660.5K after10b5-1
Jun 3, 2025 (view filing)Jun 3Same dayAlbers Jeffrey W.DirectorSSale−6.35K$49.00−$311.1K−100.0%0 after10b5-1
May 23, 2025 (view filing)May 23Same dayChadwick Jeremy GChief Operating OfficerSSale−2.58K$29.30−$75.4K−3.7%66.4K after
Mar 3, 2025 (view filing)Mar 3Same dayChiniara EllenChief Legal OfficerSSale−2.24K$30.45−$68.2K−2.7%80.1K after2 lots
Mar 3, 2025 (view filing)Mar 3Same dayChadwick Jeremy GChief Operating OfficerSSale−1.38K$30.45−$42.1K−2.0%67.8K after2 lots
Mar 3, 2025 (view filing)Mar 3Same dayJacobs Bruce N.Chief Financial OfficerSSale−7.04K$30.45−$214.2K−3.4%201.9K after2 lots
Mar 3, 2025 (view filing)Mar 3Same dayGollob JaredChief Medical OfficerSSale−5.74K$30.45−$174.8K−4.6%120.0K after2 lots
Jan 6, 2025 (view filing)Jan 6Same dayChiniara EllenChief Legal OfficerSSale−3.13K$41.75−$130.6K−5.4%54.8K after
Dec 2, 2024 (view filing)Dec 2Same dayEsposito PamelaDirectorSSale−2.50K$49.00−$122.5K−100.0%0 after10b5-1
Sep 17, 2024 (view filing)Sep 17Same dayEsposito PamelaDirectorSSale−13.5K$48.28−$651.8K−100.0%0 after2 lots10b5-1
Aug 26, 2024 (view filing)Aug 26Same dayAlbers Jeffrey W.DirectorSSale−5.00K$49.10−$245.5K−100.0%0 after10b5-1
Aug 22, 2024 (view filing)5:06 PM ETAug 202 daysBiotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and FootnotesPPurchaseCommon Stock, $0.0001 par value+358.3K$40.75+$14.6M–156.7K afterDerivative2 lots
Aug 22, 2024 (view filing)4:03 PM ETAug 202 daysBaker Julian and 5 othersDirectorPPurchase+1$46.41+$46.410.0%5.52M after
Aug 22, 2024 (view filing)4:03 PM ETAug 211 dayBaker Julian and 5 othersDirectorPPurchase+2.59M$40.75+$105.7M–9.63M afterDerivative2 lots
Jul 16, 2024 (view filing)Jul 15-161 dayGollob JaredChief Medical OfficerSSale−39.6K$45.53−$1.80M−29.3%95.5K after3 lots10b5-1
Jul 9, 2024 (view filing)Jul 9Same dayBooth BruceDirectorSSale−454.0K$38.21−$17.3M−38.6%723.2K after10 lots10b5-1
Jun 14, 2024 (view filing)Jun 12-132 daysBooth BruceDirectorSSale−26.9K$35.27−$950.2K−3.2%802.0K after6 lots10b5-1
Jun 7, 2024 (view filing)Jun 7Same dayHorobin JoannaDirectorSSale−8.50K$32.99−$280.4K−100.0%0 after2 lots10b5-1
May 23, 2024 (view filing)May 23Same dayChadwick Jeremy GChief Operating OfficerSSale−2.58K$34.99−$90.1K−5.5%44.2K after
Mar 15, 2024 (view filing)Mar 14-151 dayBooth BruceDirectorSSale−127.4K$40.25−$5.13M−13.6%806.7K after11 lots10b5-1
Mar 15, 2024 (view filing)Mar 141 dayBooth BruceDirectorSSale−154$41.51−$6.39K0.0%819.2K after10b5-1
Mar 13, 2024 (view filing)7:53 PM ETMar 11-132 daysAtlas Venture Fund X, L.P. and 5 others10% OwnerSSale−292.0K$42.20−$12.3M−5.9%4.68M after6 lots10b5-1
Mar 13, 2024 (view filing)7:53 PM ETMar 11-132 daysAtlas Venture Fund X, L.P. and 5 others10% OwnerSSale−61.3K$42.20−$2.59M−6.9%828.8K after6 lots10b5-1
Mar 13, 2024 (view filing)Mar 11-132 daysBooth BruceDirectorSSale−353.4K$42.20−$14.9M−29.9%828.8K after12 lots10b5-1
Mar 4, 2024 (view filing)Mar 4Same dayGollob JaredChief Medical OfficerSSale−3.34K$41.85−$140.0K−3.4%95.7K after3 lots
Mar 4, 2024 (view filing)Mar 4Same dayJacobs Bruce N.Chief Financial OfficerSSale−3.93K$41.85−$164.7K−2.7%142.4K after3 lots
Feb 29, 2024 (view filing)Feb 272 daysGollob JaredChief Medical OfficerSSale−400$45.00−$18.0K−0.5%74.7K after10b5-1
Feb 21, 2024 (view filing)Feb 20-211 dayAlbers Jeffrey W.DirectorSSale−5.00K$39.05−$195.3K−100.0%0 after2 lots10b5-1
Feb 9, 2024 (view filing)Feb 9Same dayGollob JaredChief Medical OfficerSSale−46.1K$35.50−$1.64M−38.2%74.7K after2 lots10b5-1
Jan 23, 2024 (view filing)Jan 23Same dayAlbers Jeffrey W.DirectorSSale−10.0K$30.05−$300.5K−100.0%0 after10b5-1
Jan 9, 2024 (view filing)4:49 PM ETJan 54 daysBiotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and FootnotesPPurchaseCommon Stock, $0.0001 par value+979.0K$25.25+$24.7M–52.7K afterDerivative3 lots
Jan 5, 2024 (view filing)Jan 41 dayChiniara EllenChief Legal OfficerSSale−3.29K$22.58−$74.4K−8.8%34.2K after
Nov 6, 2023 (view filing)6:07 PM ETNov 2-34 daysBiotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and FootnotesPPurchaseCommon Stock, $0.0001 par value+414.1K$12.80+$5.30MNew position294.6K after6 lots
Mar 3, 2023 (view filing)Mar 21 dayCaughey ElaineChief Business OfficerSSale−714$31.00−$22.1K−3.6%19.0K after2 lots
Mar 3, 2023 (view filing)Mar 21 dayGollob JaredChief Medical OfficerSSale−1.30K$31.00−$40.2K−1.7%74.7K after2 lots
Mar 3, 2023 (view filing)Mar 21 dayJacobs Bruce N.Chief Financial OfficerSSale−1.37K$31.00−$42.5K−1.3%104.6K after2 lots
Jan 13, 2023 (view filing)5:08 PM ETJan 11-122 daysBiotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and FootnotesPPurchaseCommon Stock, $0.0001 par value+41.0K$30.51+$1.25M+2.2%1.89M after4 lots
Jan 13, 2023 (view filing)4:50 PM ETJan 11-122 daysAtlas Venture Fund X, L.P. and 5 others10% OwnerSSale−98.8K$30.22−$2.99M−2.0%4.97M after2 lots
Jan 13, 2023 (view filing)4:50 PM ETJan 11-122 daysAtlas Venture Fund X, L.P. and 5 others10% OwnerSSale−27.7K$30.22−$835.9K−3.0%890.1K after2 lots
Jan 13, 2023 (view filing)Jan 11-122 daysBooth BruceDirectorSSale−126.5K$30.22−$3.82M−12.4%890.1K after4 lots
Dec 16, 2022 (view filing)5:03 PM ETDec 14-152 daysAtlas Venture Fund X, L.P. and 5 others10% OwnerSSale−298.6K$31.36−$9.36M−5.6%5.07M after6 lots